Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Next Previous
Trial Profile

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Antithymocyte globulin
  • Indications Acute myeloid leukaemia; Advanced breast cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Apr 2019 Status changed from active, no longer recruiting to discontinued.
    • 05 Jul 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
    • 05 Jul 2018 Planned primary completion date changed from 15 Jun 2018 to 15 Jun 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top